Fate Therapeutics (FATE) Corporate presentation summary

Strategic vision and platform overview

• Focus on transforming treatment for autoimmune diseases and cancer through accessible, off-the-shelf cell therapies.

• Utilizes iPSC-derived, multiplexed-engineered CAR T and CAR NK cells for scalable, on-demand therapies.

• Proprietary Sword & Shield™ technology enhances persistence and immune evasion, reducing need for conditioning.

• Advanced GMP facility enables mass production at low cost, supporting clinical and early commercial supply.

• Platform delivers uniform, homogenous drug products, overcoming limitations of autologous and allogeneic approaches.

Clinical pipeline and development progress

• FT819 (anti-CD19 CAR T) in Phase 1 for SLE, SSc, IIM, and ANCA vasculitis; 15 SLE, 4 SSc, and 1 IIM patients treated.

• FT825 (anti-HER2 CAR T) in Phase 1 for solid tumors, with ongoing dose escalation and combination studies.

• FT836 (anti-MICA/B CAR T) in Phase 1 for pan-solid tumors; early evidence of anti-tumor activity and multiple myeloma IIT initiated.

• FT839 (anti-CD19/CD38 CAR T) advancing toward IND filing for broad autoimmune and hematologic indications.

• FT522 (anti-CD19 CAR NK) cleared for Phase 1 basket study in multiple autoimmune diseases.

Key clinical data and safety profile

• FT819 shows durable SLE remission, complete renal response, and sustained B-cell depletion with favorable safety.

• No high-grade CRS, ICANS, or DLTs observed in FT819-treated patients; supports outpatient, same-day discharge.

• Early SSc patient data show meaningful improvement and no severe adverse events.

• FT825 demonstrates preferential tumor targeting and limited off-tumor toxicity in preclinical and early clinical data.

• FT836 and FT839 incorporate multi-antigen targeting and Sword & Shield™ for enhanced efficacy and safety.